Utilizing Spatial Transcriptomics to Unlock Precision Pain Therapeutics

View On Demand

Doloromics is a seed-stage startup developing novel therapeutics to treat chronic pain. The team at Doloromics has built a proprietary computational platform to identify drug targets within the human Dorsal Root Ganglion (DRG). Through a collaboration with NanoString, the company deeply sequenced and transcriptomically profiled nociceptors to uncover moderate-to-low expressed drug targets that would typically be overlooked by traditional sequencing methods. The results demonstrated by the team illuminate the ways in which the GeoMx® Digital Spatial Profiling platform can be used to facilitate an approach to precision medicine.


Jackson Brougher, PhD

Chief Scientific Officer, Doloromics

Jackson Brougher is the Chief Scientific Officer of Doloromics, a pain therapeutics startup located in Menlo Park, California. Jackson obtained his Ph.D. at the University of Texas at Dallas before co-founding the company in the spring of 2021. Through his tenure at the company, he has helped to develop Doloromic's computational platform, DOLOReS, into a multi-omic drug target discovery engine.